PubMed Health⌕ Search

Biomedical subjects

D Plundrová

Publications and source records attributed to D Plundrová.

5 recordsLinked to original sources
PubMed2000

Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.

We provide data on in vivo targeting of the Thy 1.2 (CDw90) cell surface receptor expressed on neoplastic T cells, mouse EL4 T cell lymphoma. The targeting antibody and the anticancer drug, doxorubicin (DOX) were conjugated to a water-soluble copolymer based on N-(2-hydroxypropyl)methacrylamide (HPMA) acting as a carrier responsible for controlled intracellular release of the conjugated drug. The in vivo therapeutic efficacy of HPMA copolymer-bound DOX targeted with anti-EL4 antibody, polyclonal anti-thymocyte globulin (ATG), monoclonal anti-Thy 1.2 antibody or its F(ab')(2) fragment was compared with the efficacy of DOX conjugated to HPMA copolymer containing nonspecific IgG or bovine serum albumin (BSA). Anti-EL4 antibody-targeted conjugate caused a significant retardation of tumor growth and an extension of the life span of treated mice. The effect was comparable with that of HPMA copolymer-bound DOX targeted with ATG, anti-Thy 1.2 antibody or its F(ab')(2) fragment. However, considerable antitumor effect was seen also in conjugates targeted instead of specific antibodies with syngeneic nonspecific IgG or BSA. Patients with advanced cancer are often immunocompromised due to dysfunction of their immune system induced by cancer and cytotoxic drugs. A significant decrease of unwanted side-effects of targeted drugs against a number of vital organs was already documented. In this study we have compared immunotoxic effects of free DOX with those of its antibody-targeted form on NK cells and cytolytic T lymphocytes (CTLs) isolated from C57BL/10 mice bearing EL4 T cell lymphoma. In the same model we have tested the combination therapy with immunomodulators (beta-glucan or AM-2) injected together with targeted daunomycin. We have observed a significant protective effect of targeted DOX against NK cells and CTLs. Moreover, the data revealed that combination therapy considerably enhances antitumor efficacy of the targeted anticancer drug.

Adjuvants, Immunologic↗
PubMed1991

[Phagocytosis in pregnancy].

The authors assessed the influence of pregnancy on the phagocytic activity by the fungus test in 30 women during the first third of pregnancy and in 30 women during the third trimester of pregnancy. The control group was formed by 30 non-pregnant women. It was revealed that the capacity of phagocytosis is preserved in all phagocytizing cells, their phagocytic activity declines, however, significantly during normal pregnancy. This may be due to a hitherto unknown suppressively acting factor or to exhaustion of the phagocytic activity of leucocytes due to an excess of immune complexes in serum of pregnant women.

Adolescent↗
PubMed1989

[Circulating antitrophoblast antibodies in normal pregnancy and in EPH gestosis].

Antitrophoblastic antibodies were assessed by the bond with the antigen of syncytiotrophoblastic membranes according to Davies (ELISA system) in 17 nulligravidae, in 33 men and 70 pregnant women. The pregnancy was normal in 27 women in the Ist and in 32 in the IIIrd trimester, 11 women had signs of EPH gestosis. The incidence of antitrophoblastic antibodies rises significantly with the period of gestation, in women with toxaemia the values are reduced as compared with the group in the third trimester. The authors did not find a relationship between the values of these antibodies and the concurrently assessed level of immunoglobulin IgG, IgA and IgM. Possibilities of the development of toxic immunocomplexes during EPH toxaemia are discussed.

Adolescent↗